Trial reportDermatologic therapy2021
A daily regimen of a ceramide-dominant moisturizing cream and cleanser restores the skin permeability barrier in adults with moderate eczema: A randomized trial.
Trial report in Dermatologic therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- A Split-Face Micro-Needling Study to Evaluate the Efficacy and Consumer Perception of a Novel Moisturization Agent.Journal of cosmetic dermatology · 2025Trial
- A single-center, randomized, controlled study on the efficacy of niacinamide-containing body emollients combined with cleansing gel in the treatment of mild atopic dermatitis.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2023Trial
- A daily regimen of a ceramide-dominant moisturizing cream and cleanser restores the skin permeability barrier in adults with moderate eczema: A randomized trial.Dermatologic therapy · 2021Trial
- Effectiveness of a Skin Care Program With a Cream Containing Ceramide C and a Personalized Training for Secondary Prevention of Hand Contact Dermatitis.Dermatitis : contact, atopic, occupational, drugTrial
- Oryza Ceramax in Dermatologic Care: A Multi-pathway Approach to Skin Hydration and Barrier Repair.Cureus · 2026Review
- Barrier Products for Topical Delivery-Insight into Efficacy Testing and Barrier-Boosting Compounds.Pharmaceutics · 2025Review
- Effects of a Ceramide-Containing Glycinate-Based Cleanser on the Condition of Oily Skin and Skin Post-IPL Treatments.Journal of cosmetic dermatology · 2025Article
- Atopic Dermatitis: The Relationship Between Immune Mediators and Skin Lipid Barrier.Clinical reviews in allergy & immunology · 2025Review
- Skin Barrier Repair and Nursing Care in Patients with Atopic Dermatitis: A Narrative Review.International journal of general medicine · 2025Review
- Topical Treatments in Atopic Dermatitis: An Expansive Review.Journal of clinical medicine · 2024Review
- Efficacy of Topical Application of a Skin Moisturizer Containing Pseudo-Ceramide and a Eucalyptus Leaf Extract on Atopic Dermatitis: A Review.Journal of clinical medicine · 2024Review
- The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Review
- How and what adverse events are reported and captured in randomized control trials of emollients in the treatment of eczema?Clinical and experimental dermatology · 2023Article
- Treatments for atopic dermatitis.Australian prescriber · 2023Review
- Review
- Ceramide Acyl Chain Length and Its Relevance to Intracellular Lipid Regulation.International journal of molecular sciences · 2022Review
- Moisturizer in Patients with Inflammatory Skin Diseases.Medicina (Kaunas, Lithuania) · 2022Review
- Vehicles for Drug Delivery and Cosmetic Moisturizers: Review and Comparison.Pharmaceutics · 2021Review
- Recruitment of adults with moderate eczema for a randomised trial: Comparison of traditional versus modern methods.The Australasian journal of dermatology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dysfunctional skin barrier in eczema patients may be attributed to decreased levels of ceramides in the stratum corneum. The aim of this study was to determine whether a two-part system consisting of a ceramide-dominant physiological lipid-based moisturizing cream and cleanser could ameliorate the signs and symptoms of moderate eczema in adults over 28 days compared to placebo. Assessments were conducted at baseline and every 7 days thereafter. Eczema area severity index score decreased significantly across all time points in both groups compared to baseline (P < .0001), however, this decrease was not significant between groups at day 28 (P = .7804). In contrast, transepidermal water loss and skin hydration significantly improved over time in the active group, while it either stayed the same or worsened in the placebo group (P = .0342 and P < .0001, respectively). There was no difference in the use of mometasone furoate as rescue medication over time between groups (P = .1579). Dermatology life quality index scores improved significantly in both groups (P < .0001), with no difference between groups (P = .5256). However, patient satisfaction was greater in the active compared to the placebo group for several parameters including relief of itch, dry skin, skin softness and smoothness (all P < .05). No patients withdrew from the study due to adverse events (AEs) and there were no serious AEs. The ceramide-dominant moisturizing cream and cleanser safely restores skin permeability and improves the signs and symptoms of eczema in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.